Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2018
Number of items: 4.


Moesges, R., Bachert, C., Panzner, P., Calderon, M. A., Haazen, L., Pirotton, S., Wathelet, N., Durham, S. R., Bonny, M. -A., Legon, T., von Frenckell, R., Pfaar, O. and Shamji, M. H. (2018). Short course of grass allergen peptides immunotherapy over 3weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial. Allergy, 73 (9). S. 1842 - 1851. HOBOKEN: WILEY. ISSN 1398-9995

Moesges, R., Demoly, P., Lehmacher, W., Durham, S., Shamji, M., Pirotton, S., Haazen, L. and Calderon, M. (2018). Safety of a 3-week allergen immunotherapy course with grass pollen peptides: A randomised double-blind placebo-controlled trial. Allergy, 73. S. 471 - 472. HOBOKEN: WILEY. ISSN 1398-9995

Moesges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G. and Shamji, M. H. (2018). A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy, 73 (4). S. 896 - 905. HOBOKEN: WILEY. ISSN 1398-9995

Moesges, R., Koch, A. F., Raskopf, E., Singh, J., Shah-Hosseini, K., Astvatsatourov, A., Hauswald, B., Yarin, Y., Corazza, F., Haazen, L., Pirotton, S., Allekotte, S., Zadoyan, G., Legon, T., Durham, S. R. and Shamji, M. H. (2018). Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients. Allergy, 73 (6). S. 1254 - 1263. HOBOKEN: WILEY. ISSN 1398-9995

This list was generated on Sun Nov 28 02:32:44 2021 CET.